Where are we now? and where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop

Jason T. Huse, Max Wallace, Kenneth D. Aldape, Mitchel S. Berger, Chetan Bettegowda, Daniel J. Brat, Daniel P. Cahill, Timothy Cloughesy, Daphne A. Haas-Kogan, Marco Marra, C. Ryan Miller, Sarah J. Nelson, Sofie R. Salama, Riccardo Soffietti, Patrick Y. Wen, Stephen Yip, Katharine Yen, Joseph F. Costello, Susan Chang

Research output: Contribution to journalArticle

Abstract

Diffuse gliomas consist of both low- and high-grade varieties, each with distinct morphological and biological features. The often extended periods of relative indolence exhibited by low-grade gliomas (LGG; WHO grade II) differ sharply from the aggressive, rapidly fatal clinical course of primary glioblastoma (GBM; WHO grade IV). Nevertheless, until recently, the molecular foundations underlying this stark biological contrast between glioma variants remained largely unknown. The discoveries of distinctive and highly recurrent genomic and epigenomic abnormalities in LGG have both informed a more accurate classification scheme and pointed to viable avenues for therapeutic development. As such, the field of neuro-oncology now seems poised to capitalize on these gains to achieve significant benefit for LGG patients. This report will briefly recount the proceedings of a workshop held in January 2013 and hosted by Accelerate Brain Cancer Cure (ABC2) on the subject of LGG. While much of the meeting covered recent insights into LGG biology, its focus remained on how best to advance the clinical management, whether by improved preclinical modeling, more effective targeted therapeutics and clinical trial design, or innovative imaging technology.

Original languageEnglish (US)
Pages (from-to)173-178
Number of pages6
JournalNeuro-Oncology
Volume16
Issue number2
DOIs
StatePublished - Jan 2014
Externally publishedYes

Fingerprint

Brain Neoplasms
Glioma
Education
Research
Glioblastoma
Epigenomics
Clinical Trials
Technology
Therapeutics
N,N'-bis(4-azidobenzoyl)cystine

Keywords

  • clinical trials
  • genomics
  • low-grade glioma
  • personalized medicine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Where are we now? and where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop. / Huse, Jason T.; Wallace, Max; Aldape, Kenneth D.; Berger, Mitchel S.; Bettegowda, Chetan; Brat, Daniel J.; Cahill, Daniel P.; Cloughesy, Timothy; Haas-Kogan, Daphne A.; Marra, Marco; Miller, C. Ryan; Nelson, Sarah J.; Salama, Sofie R.; Soffietti, Riccardo; Wen, Patrick Y.; Yip, Stephen; Yen, Katharine; Costello, Joseph F.; Chang, Susan.

In: Neuro-Oncology, Vol. 16, No. 2, 01.2014, p. 173-178.

Research output: Contribution to journalArticle

Huse, JT, Wallace, M, Aldape, KD, Berger, MS, Bettegowda, C, Brat, DJ, Cahill, DP, Cloughesy, T, Haas-Kogan, DA, Marra, M, Miller, CR, Nelson, SJ, Salama, SR, Soffietti, R, Wen, PY, Yip, S, Yen, K, Costello, JF & Chang, S 2014, 'Where are we now? and where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop', Neuro-Oncology, vol. 16, no. 2, pp. 173-178. https://doi.org/10.1093/neuonc/not229
Huse, Jason T. ; Wallace, Max ; Aldape, Kenneth D. ; Berger, Mitchel S. ; Bettegowda, Chetan ; Brat, Daniel J. ; Cahill, Daniel P. ; Cloughesy, Timothy ; Haas-Kogan, Daphne A. ; Marra, Marco ; Miller, C. Ryan ; Nelson, Sarah J. ; Salama, Sofie R. ; Soffietti, Riccardo ; Wen, Patrick Y. ; Yip, Stephen ; Yen, Katharine ; Costello, Joseph F. ; Chang, Susan. / Where are we now? and where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop. In: Neuro-Oncology. 2014 ; Vol. 16, No. 2. pp. 173-178.
@article{aa6e0ed4edf7480387af039f3feefec7,
title = "Where are we now? and where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop",
abstract = "Diffuse gliomas consist of both low- and high-grade varieties, each with distinct morphological and biological features. The often extended periods of relative indolence exhibited by low-grade gliomas (LGG; WHO grade II) differ sharply from the aggressive, rapidly fatal clinical course of primary glioblastoma (GBM; WHO grade IV). Nevertheless, until recently, the molecular foundations underlying this stark biological contrast between glioma variants remained largely unknown. The discoveries of distinctive and highly recurrent genomic and epigenomic abnormalities in LGG have both informed a more accurate classification scheme and pointed to viable avenues for therapeutic development. As such, the field of neuro-oncology now seems poised to capitalize on these gains to achieve significant benefit for LGG patients. This report will briefly recount the proceedings of a workshop held in January 2013 and hosted by Accelerate Brain Cancer Cure (ABC2) on the subject of LGG. While much of the meeting covered recent insights into LGG biology, its focus remained on how best to advance the clinical management, whether by improved preclinical modeling, more effective targeted therapeutics and clinical trial design, or innovative imaging technology.",
keywords = "clinical trials, genomics, low-grade glioma, personalized medicine",
author = "Huse, {Jason T.} and Max Wallace and Aldape, {Kenneth D.} and Berger, {Mitchel S.} and Chetan Bettegowda and Brat, {Daniel J.} and Cahill, {Daniel P.} and Timothy Cloughesy and Haas-Kogan, {Daphne A.} and Marco Marra and Miller, {C. Ryan} and Nelson, {Sarah J.} and Salama, {Sofie R.} and Riccardo Soffietti and Wen, {Patrick Y.} and Stephen Yip and Katharine Yen and Costello, {Joseph F.} and Susan Chang",
year = "2014",
month = "1",
doi = "10.1093/neuonc/not229",
language = "English (US)",
volume = "16",
pages = "173--178",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Where are we now? and where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop

AU - Huse, Jason T.

AU - Wallace, Max

AU - Aldape, Kenneth D.

AU - Berger, Mitchel S.

AU - Bettegowda, Chetan

AU - Brat, Daniel J.

AU - Cahill, Daniel P.

AU - Cloughesy, Timothy

AU - Haas-Kogan, Daphne A.

AU - Marra, Marco

AU - Miller, C. Ryan

AU - Nelson, Sarah J.

AU - Salama, Sofie R.

AU - Soffietti, Riccardo

AU - Wen, Patrick Y.

AU - Yip, Stephen

AU - Yen, Katharine

AU - Costello, Joseph F.

AU - Chang, Susan

PY - 2014/1

Y1 - 2014/1

N2 - Diffuse gliomas consist of both low- and high-grade varieties, each with distinct morphological and biological features. The often extended periods of relative indolence exhibited by low-grade gliomas (LGG; WHO grade II) differ sharply from the aggressive, rapidly fatal clinical course of primary glioblastoma (GBM; WHO grade IV). Nevertheless, until recently, the molecular foundations underlying this stark biological contrast between glioma variants remained largely unknown. The discoveries of distinctive and highly recurrent genomic and epigenomic abnormalities in LGG have both informed a more accurate classification scheme and pointed to viable avenues for therapeutic development. As such, the field of neuro-oncology now seems poised to capitalize on these gains to achieve significant benefit for LGG patients. This report will briefly recount the proceedings of a workshop held in January 2013 and hosted by Accelerate Brain Cancer Cure (ABC2) on the subject of LGG. While much of the meeting covered recent insights into LGG biology, its focus remained on how best to advance the clinical management, whether by improved preclinical modeling, more effective targeted therapeutics and clinical trial design, or innovative imaging technology.

AB - Diffuse gliomas consist of both low- and high-grade varieties, each with distinct morphological and biological features. The often extended periods of relative indolence exhibited by low-grade gliomas (LGG; WHO grade II) differ sharply from the aggressive, rapidly fatal clinical course of primary glioblastoma (GBM; WHO grade IV). Nevertheless, until recently, the molecular foundations underlying this stark biological contrast between glioma variants remained largely unknown. The discoveries of distinctive and highly recurrent genomic and epigenomic abnormalities in LGG have both informed a more accurate classification scheme and pointed to viable avenues for therapeutic development. As such, the field of neuro-oncology now seems poised to capitalize on these gains to achieve significant benefit for LGG patients. This report will briefly recount the proceedings of a workshop held in January 2013 and hosted by Accelerate Brain Cancer Cure (ABC2) on the subject of LGG. While much of the meeting covered recent insights into LGG biology, its focus remained on how best to advance the clinical management, whether by improved preclinical modeling, more effective targeted therapeutics and clinical trial design, or innovative imaging technology.

KW - clinical trials

KW - genomics

KW - low-grade glioma

KW - personalized medicine

UR - http://www.scopus.com/inward/record.url?scp=84893040660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893040660&partnerID=8YFLogxK

U2 - 10.1093/neuonc/not229

DO - 10.1093/neuonc/not229

M3 - Article

C2 - 24305708

AN - SCOPUS:84893040660

VL - 16

SP - 173

EP - 178

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 2

ER -